Noninvasive Delivery of Biologicals to the Brain

Sheldon Jordan; Margaret Zielinski; Marcin Kortylewski; Taylor Kuhn; Alexander Bystritsky

doi:10.1176/appi.focus.20210028

Noninvasive Delivery of Biologicals to the Brain

Focus (Am Psychiatr Publ). 2022 Jan;20(1):64-70. doi: 10.1176/appi.focus.20210028. Epub 2022 Jan 25.

Authors

Sheldon Jordan¹, Margaret Zielinski¹, Marcin Kortylewski¹, Taylor Kuhn¹, Alexander Bystritsky¹

Affiliation

¹ Department of Neurology, University of California, Los Angeles and Department of Neurology, University of Southern California, Los Angeles (Jordan);Neurological Associates-The Interventional Group, Los Angeles (Jordan, Zielinski);Department of Immuno-Oncology, Beckman Research Institute, City of Hope National Medical Center, Los Angeles (Kortylewski);Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles (Kuhn, Bystritsky).

Abstract

In the past, psychotherapy and neuropharmacological approaches have been the most common treatments for disordered thoughts, moods, and behaviors. One new path of brain therapeutics is in the deployment of noninvasive approaches designed to reprogram brain function at the cellular level. Treatment at the cellular level may be considered for a wide array of disorders, ranging from mood disorders to neurodegenerative disorders. Brain-targeted biological therapy may provide minimally invasive and accurate delivery of treatment. The present article discusses the hurdles and advances that characterize the pathway to this goal.

Keywords: Neuroimaging - PS0398; Pharmacokinetics - AJP0064; biological therapy; brain-targeted; non-invasive.

Grants and funding

R01 CA215183/CA/NCI NIH HHS/United States